European Pharmaceutical Review

FEBRUARY 29, 2024

According to the Janssen Pharmaceutical Companies of Johnson & Johnson and NICE, DVCd is recommended for the rare bone marrow disorder, only if daratumumab is stopped after 24 cycles of treatment, or earlier if the condition progresses.

Documentation 105

Documentation Pharmaceutical Companies Pharmaceutical Companies 105

Pharmaceutical Technology

NOVEMBER 25, 2022

In the next two years, the surveyed healthcare industry professionals believed that their companies will prioritise AI as the main investment target (figure 2).

Pharmaceutical Companies 145

Pharmaceutical Companies Pharmaceutical Companies 145

European Pharmaceutical Review

JANUARY 18, 2023

The first good manufacturing practice (GMP) registration of a UK pharmaceutical facility for high Δ9-tetrahydrocannabinol (THC) cannabis active pharmaceutical ingredient (API) has been granted since the legalisation of medical cannabis in 2018. The firm’s medicinal cannabis product will be supplied in oil form as an API.

Labelling 119

Labelling Pharmaceutical Companies Pharmaceutical Companies 119

pharmaphorum

JANUARY 17, 2022

Founded in 2018 as a spin-off of the University of Zurich and Harvard University, EraCal is already using this technology to develop a novel anti-obesity drug, named Era-379. Partnering with EraCal builds upon the success of Novo Nordisk’s Wegovy (semaglutide) chronic weight management drug, which was approved by the FDA in June 2021.

Diabetes 123

Diabetes Pharmaceutical Companies Pharmaceutical Companies 123

Drug Patent Watch

NOVEMBER 9, 2023

This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2018 to 2023. Companies that successfully challenge patents on branded drugs are granted six… The post Most prolific drug patent challengers appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies 59

European Pharmaceutical Review

FEBRUARY 21, 2023

After the substance became legal in the UK in 2018, pharmaceutical companies have faced numerous obstacles to attain a fairer position in the industry. There is a clear framework in place now, and as a pharmaceutical company, we are certainly not looking to the MHRA to loosen or change any of the guidelines.

Pharmaceutical Companies 132

Pharmaceutical Companies Pharmaceutical Companies Compounding Drug Development 132

pharmaphorum

OCTOBER 20, 2020

The pandemic has triggered a change in how pharmaceutical companies are engaging with healthcare professionals. When IQVIA polled non COVID-19 treating Italian HCPs in March when the crisis was at its worst, it asked HCPs if they still welcomed pharmaceutical company engagement during the crisis. The answer was yes.

Pharmaceutical Companies 122

Pharmaceutical Companies Pharmaceutical Companies Documentation Communication 122

Drug Patent Watch

JULY 26, 2023

This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2018 to 2023. Companies that successfully challenge patents on branded drugs are granted six… The post Most prolific drug patent challengers appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

NOVEMBER 3, 2021

The report refers to data collected across 350+ global pharma companies between November 2020 through January 2021, and notes a 70% compound average growth rate in the volume of content managed in Veeva Vault PromoMats since 2018. Veeva is the global leader in cloud software for the life sciences industry.

Compounding 98

Compounding Communication Pharmaceutical Companies Pharmaceutical Companies 98

European Pharmaceutical Review

AUGUST 1, 2022

The 2018 study of Phase III and IV clinical trials also identified additional barriers for disability diversity, including inaccessible trial sites, medical equipment and “ableist” biases. “The A study published in the Journal of the American Medical Association found that 12.4

Drug Development 122

Drug Development Pharmaceutical Companies Pharmaceutical Companies 122

European Pharmaceutical Review

SEPTEMBER 28, 2022

The method was able to detect, separate and quantify NDMA in the active pharmaceutical ingredient (API), manufactured tablets and marketed tablets. In 2018, one batch of the generic drug valsartan was recalled due to unacceptable levels of the nitrosamine impurity NDMA. González et al.

Compounding 105

Compounding Pharmaceutical Companies Pharmaceutical Companies 105

Pharma Marketing Network

MAY 15, 2023

Big data has become an increasingly important tool for businesses across various industries, and the pharmaceutical industry is no exception. However, the use of big data in pharmaceutical marketing also poses significant challenges that must be considered. Another challenge is the sheer volume of data that companies must manage.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies Drug Development 59

European Pharmaceutical Review

JULY 12, 2022

More than 480 warning letters solely related to the failure to produce aseptic conditions because of deficient cleaning and disinfection systems for cleanrooms and their equipment, were issued by regulators between 2013 to 2018. Microbial resistance is one of the factors responsible for such failings.

Pharmaceutical Manufacturing 111

Pharmaceutical Manufacturing Pharmaceutical Companies Pharmaceutical Companies 111

Pharma Pathway

SEPTEMBER 12, 2022

Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics. Eligibility: 2018, 2019, 2020, 2021, 2022 passed outs Only. Chemist/ Jr.

Biosimilars 52

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 52

Pharma Marketing Network

MARCH 23, 2023

Big data has become an increasingly important tool for businesses across various industries, and the pharmaceutical industry is no exception. However, the use of big data in pharmaceutical marketing also poses significant challenges that must be considered. Another challenge is the sheer volume of data that companies must manage.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

Pharmaceutical Technology

NOVEMBER 21, 2022

Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR).

Drug Pricing 69

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 69

pharmaphorum

SEPTEMBER 16, 2020

Delayed clinical trial data delivery is a growing problem for pharmaceutical companies and one that can have catastrophic consequences for the development of their promising pipeline candidates. But there are ways to improve this situation, as Remarque Systems’ recent Is a lack of real-time data holding trials back?

Data Entry 71

Data Entry Pharmaceutical Companies Pharmaceutical Companies 71

Pharmaceutical Business Review

SEPTEMBER 15, 2023

In 2018, BeiGene received the rights to leverage the Harbour Mice heavy chain (H2L2) platform for several antibody programmes. Our platform has enabled biotechnology and pharmaceutical companies as well as academia to accelerate innovative drug discovery for more than a decade.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

European Pharmaceutical Review

SEPTEMBER 21, 2023

Pharmaceutical companies need to work closely with governments and health authorities to find innovative contracting and payment models, such as outcome-based agreements, which consider the clinical and economic value of the treatment to patients, healthcare systems and society. Anguela XM, High KA. Annu Rev Med. 2019; 70:273–288.

Drug Development 96

Drug Development Pharmaceutical Companies Pharmaceutical Companies Diabetes 96

pharmaphorum

OCTOBER 30, 2020

With COVID-19 anticipated to change how pharmaceutical companies engage with healthcare professionals, Ipsen UK&I is preparing for a more remote and virtual healthcare system. Prior to the pandemic, 95% of all the company’s UK customer facing teams’ interactions took place in person at NHS hospitals. “My Going remote.

Hospitals 126

Hospitals Pharmaceutical Companies Pharmaceutical Companies 126

pharmaphorum

JANUARY 6, 2023

So, what can a pharmaceutical company best control that directly affects its bottom line? When any organisation looks to slash its budget, the old adage about acquiring new customers costing five times as much as retaining existing customers becomes an alluring data point. in 1979 to 2.8%in Ensuring patient access.

Diabetes 105

Diabetes Pharmaceutical Companies Pharmaceutical Companies 105

Pharmaceutical Business Review

OCTOBER 9, 2024

The HEAL Initiative is an NIH-wide effort launched in April 2018, aiming to accelerate scientific solutions to the crisis of opioid and stimulant use disorders and pain management. The PSPP programme, integral to the HEAL Initiative, is designed to evaluate non-opioid assets through a series of established preclinical pain models.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

DECEMBER 28, 2022

In 2018, over 60% of all new molecular entities came from smaller biopharma firms, compared with just over 30% in 2009. So, how do smaller pharmaceutical companies at the cutting edge get ready for their acquisition milestone, so they maximise their value and attractiveness?

Pharmaceutical Manufacturing 119

Pharmaceutical Manufacturing Documentation Pharmaceutical Companies Pharmaceutical Companies 119

Pharmaceutical Technology

MARCH 1, 2023

Venture financing for early-stage innovator drugs for biotech companies based in the Asia-Pacific (APAC) region between 2018 to 2022 received three times less funding, at $23bn, than their US counterparts, at $72bn, according to GlobalData’s Pharma Intelligence Centre Deals Database.

Pharmaceutical Companies 72

Pharmaceutical Companies Pharmaceutical Companies 72

Pharmaceutical Technology

NOVEMBER 21, 2022

Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR).

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 52

European Pharmaceutical Review

AUGUST 14, 2023

Swedish pharmaceutical company Vicore Pharma is developing treatments for diseases where the angiotensin II type 2 receptor (AT2R) has a central role in stopping and reversing disease pathology and where there is a large unmet medical need. The company’s lead candidate, C21, is an angiotensin II type 2 receptor agonist (ATRAG).

Labelling 98

Labelling Immunity Immunization Pharmaceutical Companies 98

pharmaphorum

SEPTEMBER 29, 2020

The pharmaceutical industry is one of the most scientifically innovative and competitive industries, particularly in oncology. As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and gene therapies.

Drug Development 132

Drug Development Chemotherapy Pharmaceutical Companies Pharmaceutical Companies 132

Express Pharma

SEPTEMBER 6, 2023

What’s more, with many key biologics scheduled to lose patent protection in this decade, Indian pharmaceutical companies ought to seize this opportunity and leverage innovative technologies to introduce quality and way more affordable biosimilars in the domestic as well as global markets.

Insurance Coverage and Processing 59

Insurance Coverage and Processing Biosimilars Generic Medicine Drug Pricing 59

STAT

FEBRUARY 27, 2025

The public and pharmaceutical companies are calling for changes in drug regulation and the costs of medicines. Companies want to see products approved faster for financial reasons, and patients want medicines that can improve their lives. They are right to do so.

Pharmaceutical Companies 273

Pharmaceutical Companies Pharmaceutical Companies 273

pharmaphorum

AUGUST 25, 2020

We carried out opinion research on the Code in 2018, and found that the interviewees associated positive changes in industry practice with developments in the Code. That has contributed to improving the perception of the industry and of HCPs.

Pharmaceutical Manufacturing 90

Pharmaceutical Manufacturing Pharmaceutical Companies Pharmaceutical Companies 90

pharmaphorum

AUGUST 31, 2021

The US regulator has not only taken a proactive role in exploring the current and future applications of RWD, but also published the framework for its Real-World Evidence Program in 2018, which launched through the 21st Century Cures Act. Myth 3: RWD is too imperfect to be used to as a comparator arm to a clinical trial.

Insurance Coverage and Processing 89

Insurance Coverage and Processing Drug Development Documentation Labelling 89

Pharmaceutical Technology

OCTOBER 25, 2022

One solution that increasing numbers of pharmaceutical companies, healthcare providers, and clinical research organisations are turning to is Cassie by Syrenis, which is a Consent Management Platform (CMP). However, these companies are now finding this to be restrictive for data management. That's why we're different.”.

HIPAA 52

HIPAA Pharmaceutical Companies Pharmaceutical Companies Medical Records 52

European Pharmaceutical Review

SEPTEMBER 25, 2023

Gregory’s industrial career spans an employment history with several major pharmaceutical companies. Raw Material Identity Verification in the pharmaceutical industry [Internet]. European Pharmaceutical Review. Int J Spectrosc. 2012; 2012: 1–7. Cited 2023Feb]. Available from: [link] Robinson MD, Cistola DP.

Compounding 98

Compounding Pharmaceutical Companies Pharmaceutical Companies 98

European Pharmaceutical Review

DECEMBER 21, 2022

“As the contribution of costs of organic chemicals used as feedstock to the operating expenditures is small, the pharmaceutical companies can spearhead and guide the transition.” Experiences and consequences of phasing out substances of concern in a multinational healthcare company. Environ Sci Eur 34, 101 (2022).

Compounding 97

Compounding Pharmaceutical Manufacturing Pharmaceutical Companies Pharmaceutical Companies 97

European Pharmaceutical Review

JULY 4, 2024

She specialises in regulatory compliance and assists medical device, biotech and pharmaceutical companies as well as food & beverage companies with meeting their UK and EU regulatory obligations. 2018 [cited 2024May]. About the author Taly Dvorkis is Life Sciences Regulatory Director at Fieldfisher.

Drug Development 103

Drug Development Biosimilars Documentation Labelling 103

pharmaphorum

JULY 9, 2021

In 2018, he co-founded Ampersand Health and developed My IBD Care. Prior to Ampersand, Nader founded a startup that worked with the NHS and pharmaceutical companies to implement digital strategies, platforms and pathways that supported tens of millions of patients and tens of thousands of clinicians globally.

Hospitals 69

Hospitals Communication Immunization Immunity 69

Pharmaceutical Technology

MAY 5, 2023

The January 2019 scheme kept NHS expenditure on branded medicines within an agreed limit, which increased by 2% per annum from 2018-23. To keep within this limit, pharmaceutical companies have had to pay rebates on their sales back to the NHS on all expenditures above the capped limit.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Communication 52